Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. Assess long-term safety of oral apremilast in psoriasis patients. Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluati...

Ausführliche Beschreibung